Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Summit Therapeutics ( (SMMT) ) just unveiled an announcement.
Summit Therapeutics announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting significant milestones in 2024, including a 584% stock performance increase and over $435 million in financing. The company has made significant progress with ivonescimab, a cancer therapy currently in nine Phase III trials, showcasing a decisive improvement against pembrolizumab in NSCLC patients, and achieving regulatory approval in China.
More about Summit Therapeutics
Summit Therapeutics is a company operating in the biotechnology industry, focusing on oncology and the development of investigational therapies. Their primary product in development is ivonescimab, which is aimed at treating serious unmet medical needs in cancer patients. The company has a market focus on North America, Central & South America, Europe, the Middle East, Africa, and Japan.
YTD Price Performance: -2.72%
Average Trading Volume: 2,178,539
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.16B
For detailed information about SMMT stock, go to TipRanks’ Stock Analysis page.
